Significo Announces Close of Funding Round, bringing the Valuation to $100 Mn

With this funding, Significo aims to accelerate its strategy of consolidating high-potential digital health companies and expanding its own clinical-grade platforms.

Texas-based AI healthtech and digital therapeutic company Significo has announced the close of its Series B funding round, led by JSTAR Capital Investments’ Horizon Fund II, bringing the company’s valuation to $100 million.

With this funding, Significo aims to accelerate its strategy of consolidating high-potential digital health companies and expanding its own clinical-grade platforms.

Reportedly, the company is actively reviewing and considering acquisitions that complement its current offerings, notably Balm, its digital therapeutic and condition management solution, and Recco, its personalized health recommendation engine.

Rick McCartney, CEO of Significo, commenting regarding the new funding, said, “Patients, providers, and payors are looking for scalable, clinically validated solutions that deliver real outcomes. With JSTAR Capital Investments' backing, Significo is not only poised to scale our own platforms but also to bring together best-in-class digital health innovations under one roof. Our goal is to simplify technology adoption for healthcare providers to drive meaningful health outcomes at the population scale.”

Asper reports, the Series B financing is backed by strong commercial traction for Significo, including partnerships with leading insurers, health systems, and distribution networks.

By consolidating proven digital therapeutics into a unified, comprehensive platform, Significo aims to reduce fragmentation, improve patient engagement, and prove out a sustainable model for digital therapeutic reimbursement and adoption.

"We are excited to lead this financing round and support Significo in its mission to transform the digital health landscape," said Jared Leger, Managing Director at JSTAR Capital Investments.

Further, Evan Pritchard, Managing Director of JSTAR Capital Investmentsadded, "The team has a proven track record of execution, and their vision for consolidation and clinical impact is exactly what the industry needs."

Stay tuned for more such updates on Digital Health News